Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8WTT0
UPID:
CLC4C_HUMAN
Alternative names:
Blood dendritic cell antigen 2; C-type lectin superfamily member 7; Dendritic lectin
Alternative UPACC:
Q8WTT0; D3DUU3; Q3T1C3; Q6UXS8; Q8WXX8
Background:
C-type lectin domain family 4 member C, also known as Blood dendritic cell antigen 2, plays a crucial role in the immune system. It functions as a lectin-type cell surface receptor, involved in antigen capturing by dendritic cells. This protein specifically recognizes non-sialylated galactose-terminated biantennary glycans and binds to serum IgG, facilitating efficient targeting of ligand into antigen-processing compartments for T-cell presentation. It may also inhibit IFN-alpha/beta expression in plasmacytoid dendritic cells and act as a signaling receptor.
Therapeutic significance:
Understanding the role of C-type lectin domain family 4 member C could open doors to potential therapeutic strategies.